Glaukos Co. (NYSE:GKOS) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 3.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 397,842 shares of the medical instruments supplier's stock after acquiring an additional 12,376 shares during the period. Bank of New York Mellon Corp owned approximately 0.72% of Glaukos worth $59,652,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System increased its position in Glaukos by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after purchasing an additional 100 shares during the period. Handelsbanken Fonder AB grew its holdings in shares of Glaukos by 0.7% in the 4th quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier's stock worth $2,204,000 after acquiring an additional 100 shares during the period. HighTower Advisors LLC grew its holdings in shares of Glaukos by 3.3% in the 3rd quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier's stock worth $416,000 after acquiring an additional 103 shares during the period. New York State Teachers Retirement System grew its holdings in shares of Glaukos by 0.4% in the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier's stock worth $6,272,000 after acquiring an additional 200 shares during the period. Finally, KBC Group NV grew its holdings in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after acquiring an additional 201 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In related news, COO Joseph E. Gilliam sold 3,328 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at $4,656,707.36. This trade represents a 5.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,744 shares of company stock valued at $2,792,151. 6.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Morgan Stanley cut Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price target on the stock. in a report on Monday, December 2nd. BTIG Research upped their price target on Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Needham & Company LLC upped their price target on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Stephens upgraded Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Truist Financial upped their price target on Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $163.25.

Glaukos Trading Up 0.9 %

Shares of Glaukos stock traded up $0.94 during trading hours on Friday, reaching $104.14. 1,401,764 shares of the company's stock were exchanged, compared to its average volume of 797,940. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $5.89 billion, a price-to-earnings ratio of -36.29 and a beta of 0.99. The company has a fifty day moving average of $146.88 and a 200-day moving average of $138.89. Glaukos Co. has a 52-week low of $84.08 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Sell-side analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.